Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study

Related articles

1. Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trial

   This article has 57 authors:

   1. Antonio Avallone
   2. Alfonso De Stefano
   3. Michele Orditura
   4. Emiliano Tamburini
   5. Giuseppe Santabarbara
   6. Alfredo Colombo
   7. Maria Maddalena Laterza
   8. Teresa Troiani
   9. Francesca Bergamo
   10. Vincenzo Montesarchio
   11. Claudio Lotesoriere
   12. Tiziana Pia Latiano
   13. Alberto Zaniboni
   14. Matteo Landriscina
   15. Filippo Pietrantonio
   16. Salvatore Pisconti
   17. Rossana Berardi
   18. Domenico Bilancia
   19. Silvana Leo
   20. Alessandro Pastorino
   21. Federica Tosi
   22. Lorenzo Antonuzzo
   23. Carlo Garufi
   24. Francesco Giuliani
   25. Luigi Pio Guerrera
   26. Maria Giulia Zampino
   27. Raffaele Addeo
   28. Livio Blasi
   29. Katia Cannita
   30. Marta Caporale
   31. Alessio Cogoni
   32. Chiara Cremolini
   33. Bruno Daniele
   34. Emanuela Dell’Aquila
   35. Massimo Di Maio
   36. Davide Pastorelli
   37. Michele Pavarana
   38. Ferdinando Riccardi
   39. Giampaolo Tortora
   40. Stefano Cordio
   41. Pierosandro Tagliaferri
   42. Claudia Castiglioni
   43. Antonella Argentiero
   44. Laura Forti
   45. Maria Banzi
   46. Marco Tampellini
   47. Salvatore Corallo
   48. Stefania Mosconi
   49. Martina Torchio
   50. Umberto Malapelle
   51. Giancarlo Troncone
   52. Antonella De Luca
   53. Nicola Normanno
   54. Elena Di Gennaro
   55. Diana Giannarelli
   56. Alfredo Budillon
   57. Roberto Bordonaro

2. The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy

   This article has 6 authors:

   1. Lishan Xue
   2. Jinquan Yao
   3. Yuxin Geng
   4. Qian Xu
   5. Ning Tang
   6. Feifei Teng

3. Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer

   This article has 9 authors:

   1. Süleyman Can
   2. Veli Çakıcı
   3. Gizem Bakır Kahveci
   4. Şeyma Eroğlu
   5. Burak Tok
   6. Gökhan Uygun
   7. Esra Özer
   8. Yalçın Çırak
   9. Ivo Gökmen